Reye’s Syndrome Warning Will Not Apply To Salicylate Inactive Ingredients
This article was originally published in The Tan Sheet
Executive Summary
OTC drugs containing salicylates as inactive ingredients will not be required to carry a Reye's syndrome warning in their labeling, according to a final rule published in the April 17 Federal Register
You may also be interested in...
OTC Supplemental Warning Regs Need Not Show Causation – FDA’s Troy
FDA does not have to prove causality in order to require new warnings in the labeling of OTC drugs, Chief Counsel Daniel Troy clarified at the Generic Pharmaceutical Association's legal symposium in Washington, D.C. May 16
OTC Supplemental Warning Regs Need Not Show Causation – FDA’s Troy
FDA does not have to prove causality in order to require new warnings in the labeling of OTC drugs, Chief Counsel Daniel Troy clarified at the Generic Pharmaceutical Association's legal symposium in Washington, D.C. May 16
OTC Supplemental Warning Regs Need Not Show Causation – FDA’s Troy
FDA does not have to prove causality in order to require new warnings in the labeling of OTC drugs, Chief Counsel Daniel Troy clarified at the Generic Pharmaceutical Association's legal symposium in Washington, D.C. May 16